PRIMARY ENDPOINT DATA*: Hospitalization study (ATHENA)1

24% RRR of CV HOSPITALIZATION OR ALL-CAUSE MORTALITY (combined endpoint), entirely attributable to reduction in CV hospitalization vs placebo.

MULTAQ® reduced the relative risk for CV hospitalization or all-cause mortality by 24% (HR=0.76; 95% CI: 0.68-0.83; P<0.0001). Hospitalization/mortality rates were 31.6% with MULTAQ vs 39.2% with placebo.

POST-HOC ANALYSIS: CAD PATIENTS EXPERIENCED A 27% RRR IN CV HOSPITALIZATION AND ALL-CAUSE MORTALITY2

The relative risk reduction for CV-related hospitalization and all-cause mortality was 24% in ATHENA, which included 27% in patients with documented CAD, and 22% in non-CAD patients.3

ATHENA POST-HOC ANALYSIS

This analysis assessed safety and cardiovascular outcomes of MULTAQ in a total of 1405 patients with CAD from the ATHENA study (N=4628).3

STUDY LIMITATIONS:

Post-hoc analysis where potential bias could be introduced, given that patients were randomized based on CAD status. The analysis was retrospective, exploratory, and based on a much smaller population than the full randomized population in the ATHENA trial.

In patients who had a history of CAD, patients receiving MULTAQ had similar rates of any TEAEs and serious TEAEs as patients receiving placebo, but had significantly higher rates of bradycardia, QT interval prolongation, gastrointestinal events, and increases in serum creatinine.3

View a full list of AEs from the ATHENA trial